Singapore markets open in 4 hours 39 minutes

Esperion Therapeutics, Inc. (0ET.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
1.8320+0.0670 (+3.80%)
At close: 08:10AM CEST
Currency in EUR

Valuation measures4

Market cap (intra-day) 384.90M
Enterprise value 424.21M
Trailing P/E N/A
Forward P/E 8.27
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.08
Price/book (mrq)86.74
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.82
52-week change 326.43%
S&P500 52-week change 326.27%
52-week high 32.9880
52-week low 30.6660
50-day moving average 32.0719
200-day moving average 31.6680

Share statistics

Avg vol (3-month) 3113
Avg vol (10-day) 375
Shares outstanding 5189.46M
Implied shares outstanding 6218.07M
Float 8184.16M
% held by insiders 10.45%
% held by institutions 138.85%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -179.87%
Operating margin (ttm)-131.37%

Management effectiveness

Return on assets (ttm)-42.86%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)116.33M
Revenue per share (ttm)1.13
Quarterly revenue growth (yoy)71.40%
Gross profit (ttm)N/A
EBITDA -155.4M
Net income avi to common (ttm)-209.25M
Diluted EPS (ttm)-1.8900
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)82.25M
Total cash per share (mrq)0.44
Total debt (mrq)540.95M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.29
Book value per share (mrq)-3.85

Cash flow statement

Operating cash flow (ttm)-135.49M
Levered free cash flow (ttm)-107.14M